Table 4.
Comparison of neonatal outcomes of newborns of patients with SARS-CoV-2 infection during pregnancy and of healthy controls. Data presented as median and IQR or as number (%).
| COVID-19 during Pregnancy (n = 23) |
Healthy Controls (n = 46) |
p-Value | |
|---|---|---|---|
| Sex | 0.097 | ||
| Male, n (%) | 10 (43.5%) | 31 (67.4%) | |
| Female, n (%) | 11 (47.8%) | 14 (30.4%) | |
| Unknown, n (%) | 2 (9.5%) | 1 (2.2%) | |
| Gestational age at birth, weeks (IQR) | 39.0 (37.5–40.0) | 39.0 (38.0–40.0) | 0.400 |
| Birthweight, g (IQR) | 3370.0 (3030.0–3675.0) | 3470.0 (3190.0–3655.0) | 0.597 |
| FGR, n/n Total (%) | 2/21 (9.5%) | 0/45 (0.0%) | 0.036 |
| Mode of delivery | 0.226 | ||
| vaginal delivery, n (%) | 9 (39.1%) | 28 (60.9%) | |
| ventouse, n (%) | 3 (13.0%) | 2 (4.3%) | |
| elective cesarean section, n (%) | 1 (4.4%) | 0 (0.0%) | |
| primary cesarean section, n (%) | 4 (17.4%) | 10 (21.7%) | |
| secondary cesarean section, n (%) | 4 (17.4%) | 5 (10.9%) | |
| Unknown, n (%) | 2 (8.7%) | 1 (2.2%) | |
| APGAR score < 7 5 min after birth, n (%) | 0 (0.0%) | 0 (0.0%) | - |
| NICU admission, n/n Total (%) | 0/16 (0.0%) | 2/44 (4.5%) | 0.386 |
| Stillbirth, n (%) | 0 (0.0%) | 0 (0.0%) | - |